x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). The disorder of sugar, fat and protein metabolism caused can affect normal physiological activities and manifest as a variety of acute and chronic complications.
Type 1 Diabetes
An autoimmune condition where the immune system attacks and destroys insulin-producing beta cells in the pancreas, requiring lifelong insulin therapy.
Type 2 Diabetes
The most common form, characterized by insulin resistance and progressive beta cell dysfunction, often associated with lifestyle factors.
Gestational Diabetes
Glucose intolerance first recognized during pregnancy, requiring careful management to protect both mother and child.
Complications of Diabetes
The serious harm of diabetes is to cause many complications, including infectious diseases, atherosclerosis, microvascular disease, neurological complications and so on.
Diabetes affects multiple organ systems, leading to various complications if not properly managed.
We offer specialized preclinical research services across the full spectrum of diabetes and related complications, providing the insights you need to advance your therapeutic candidates.
Focused on immune-mediated beta cell destruction and replacement therapies.
Key Research Services:
Addressing insulin resistance and progressive beta cell dysfunction.
Key Research Services:
Specialized models investigating pregnancy-induced insulin resistance, maternal-fetal outcomes, and long-term metabolic consequences for mother and offspring.
Key Research Services:
Comprehensive evaluation of renal structure and function in diabetic kidney disease models, including albuminuria, glomerular filtration, and histopathological analysis.
Specialized imaging and histological assessment of retinal vascular changes, neurodegeneration, and inflammation in experimental models of diabetic eye disease.
Quantitative assessment of lens opacity development, biochemical changes, and therapeutic efficacy in preclinical models of diabetes-induced cataracts.
Comprehensive assessment of peripheral and autonomic nerve function, including behavioral testing, electrophysiology, and histological evaluation of nerve damage.
Evaluation of diabetic cardiomyopathy, atherosclerosis, hypertension, and vascular dysfunction in preclinical models of diabetes.
Specialized models of diabetic foot ulcers, peripheral arterial disease, and Charcot neuroarthropathy with comprehensive wound healing assessment.
Exploring cutting-edge research directions and novel therapeutic targets revolutionizing diabetes treatment
Multi-target Agonists
GLP-1R/GIPR, GLP-1R/GIPR/GCGR dual/triple targets for combined glycemic control, weight management, and cardiovascular protection
Insulin Resistance Modulators
SGLT2, PPARα/γ/δ pan-agonists, GPR119 for improved insulin sensitivity and glucose uptake
Beta Cell Protection & Regeneration
PPARα/γ/δ pan-agonists, GPR119 for improved insulin sensitivity and glucose uptake
Diabetes Complications
Specialized models of diabetic cardiomyopathy, atherosclerosis, hypertension, and vascular dysfunction in preclinical models of diabetes.
Immunomodulation Therapies
Immune checkpoint inhibitors and antigen-specific tolerance
induction for Type 1 diabetes
Cell Replacement Therapies
Stem cell-derived beta cells and artificial pancreas
implantation systems
Precision Complications Management
Anti-fibrotic, anti-vascular damage, and
neuroprotective targeted therapies
There are nearly 3,000 diabetes treatment drugs in all stages of global research and development (including under development, suspension, withdrawal, and termination), of which about 1,500 are for T2DM and about 400 are for T1DM. And a small number of drugs are used for the treatment of special types of diabetes, such as gestational diabetes, latent autoimmune adult diabetes, etc.
In addition to hypoglycemic drugs such as metformin, which are already widely used in treatment, the field of diabetes research continues to explore therapies. Recombinant insulin and insulin analogs are the main drugs for clinical treatment of diabetes. There are some immunotherapy drugs (e.g., antibody drugs) in clinical research for diabetes.
| Monoclonal antibodies | Anti-inflammatory | Tolerance inducer | Insulin secretagogues | β-cell protective agent | Treg inducers |
| Anti-CD3 | Anti-IL-1 | GAD65 | GLP-1 analogs | Polyamine | IL-2 |
| Anti-CD20 | IL-1 antagonist | Insulin | DPP-IV inhibitor | EGF | IL-10 |
| ATG/ATS | HDAC inhibitor | HSP60 | Exenatide | GLP-1/ agonist | TGF-β |
| CTLA-4 | DNT | AAT | GM-CSF | ||
| CTLA4-Ig | Anti-TNF-α | GAD | |||
| PPI | Proinsulin |
Comprehensive solutions to accelerate your diabetes research programs
From target validation to preclinical development, we provide integrated research services covering all stages.
Access to over 20 specialized animal models for diabetes and its complications, tailored to your research needs.
Fully traceable data with uncompromised integrity, accepted for regulatory submissions across the globe.
Our team of pharmacologists and diabetes experts provide personalized guidance throughout your research program.
Our team of diabetes research experts is ready to help design a customized preclinical program tailored to your therapeutic approach and research objectives.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
